The Nifty Pharma index has surged nearly 11% over the past month, significantly outperforming the Nifty 50, which declined 3.6% during the same period. According to reports from Livemint, on a year-to-date basis, the Nifty Pharma index has gained 9.4%, while the benchmark Nifty 50 has fallen by an equal margin. The pharma sector has also outperformed most peers, many of which remain under pressure due to global headwinds, elevated energy prices, and subdued earnings growth.
With the exception of two constituents, all stocks in the Nifty Pharma index posted positive returns over the past month. As reported by Livemint, Gland Pharma emerged as the top performer, rallying over 27%, followed by Laurus Labs and Biocon, which gained 21–23%. Shares of Ajanta Pharma, Cipla, Mankind Pharma, Granules India, Sun Pharmaceutical Industries, Zydus Lifesciences, and JB Chemicals & Pharmaceuticals advanced between 10% and 15%. Torrent Pharmaceuticals, Divi's Laboratories, Dr Reddy's Laboratories, Abbott India, Ipca Laboratories, Aurobindo Pharma, Natco Pharma, and Glenmark Pharmaceuticals shares rose between 6% and 10%. The only laggards in the Nifty Pharma index were Lupin, whose shares declined 0.57%, and Alkem Laboratories, which fell 2.91%.
The recent rally in pharma stocks has been driven by a combination of stronger-than-expected quarterly earnings, rupee depreciation, and an improving business outlook across companies. According to Dr. Ravi Singh, Chief Research Officer at Master Capital Services, as reported by Livemint, "Nifty Pharma has witnessed a strong rally over the last month, outperforming several sectors despite broader market volatility. The rise has been driven by a mix of better-than-expected quarterly numbers, a weaker rupee, and improving business prospects across pharmaceutical companies." Maitri Sheth, Pharma Analyst at Choice Institutional Equities, noted that pharmaceutical companies have reported better-than-expected Q4 and FY26 performance in both revenue and margins, aided by specialty launches, an improving chronic portfolio mix, and sustained demand trends.
Pharma stocks have historically been viewed as a defensive play during periods of uncertainty, given that healthcare demand tends to remain stable irrespective of economic cycles or geopolitical disruptions. As reported by Livemint, Singh explained that "People continue to spend on medicines and healthcare even during challenging periods, which gives the sector a defensive character." Another supportive factor for the sector is currency movement, as a weaker rupee generally benefits export-focused pharmaceutical companies, as overseas revenues translate into stronger earnings. However, Singh cautioned that "Pharma can help reduce portfolio volatility and provide stability during uncertain periods, but no sector is entirely insulated from broad market pressures."
In an increasingly uncertain macroeconomic and geopolitical environment, Sheth believes pharma remains among the strongest defensive sectors due to its non-cyclical demand profile. According to Livemint, "While some pressure on margins and profitability may arise from higher raw material costs and supply chain disruptions, the impact is expected to remain manageable, as recent product launches are concentrated in high-margin segments such as biosimilars, oncology, and peptides." The only laggards in the Nifty Pharma index were Lupin, whose shares declined 0.57%, and Alkem Laboratories, which fell 2.91%.
